Canton Hathaway’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $112K | Hold |
4,654
| – | – | 0.02% | 161 |
|
|
2026
Q1 | $131K | Buy |
4,654
+900
| +24% | +$24K | 0.03% | 150 |
|
|
2025
Q4 | $93.5K | Buy |
3,754
+200
| +6% | +$5.04K | 0.02% | 165 |
|
|
2025
Q3 | $91K | Hold |
3,554
| – | – | 0.02% | 174 |
|
|
2025
Q2 | $86K | Buy |
3,554
+475
| +15% | +$11.1K | 0.02% | 167 |
|
|
2025
Q1 | $78K | Hold |
3,079
| – | – | 0.02% | 174 |
|
|
2024
Q4 | $82K | Sell |
3,079
-8,475
| -73% | -$230K | 0.02% | 133 |
|
|
2024
Q3 | $334K | Hold |
11,554
| – | – | 0.08% | 77 |
|
|
2024
Q2 | $323K | Buy |
11,554
+1,000
| +9% | +$27.5K | 0.09% | 74 |
|
|
2024
Q1 | $293K | Buy |
10,554
+3,000
| +40% | +$83.2K | 0.08% | 84 |
|
|
2023
Q4 | $217K | Buy |
7,554
+5,000
| +196% | +$151K | 0.07% | 91 |
|
|
2023
Q3 | $85K | Buy |
2,554
+583
| +30% | +$20.6K | 0.03% | 116 |
|
|
2023
Q2 | $72K | Hold |
1,971
| – | – | 0.02% | 131 |
|
|
2023
Q1 | $80K | Hold |
1,971
| – | – | 0.03% | 119 |
|
|
2022
Q4 | $101K | Buy |
1,971
+40
| +2% | +$1.92K | 0.04% | 117 |
|
|
2022
Q3 | $85K | Sell |
1,931
-850
| -31% | -$41.3K | 0.03% | 128 |
|
|
2022
Q2 | $146K | Hold |
2,781
| – | – | 0.05% | 110 |
|
|
2022
Q1 | $144K | Hold |
2,781
| – | – | 0.04% | 120 |
|
|
2021
Q4 | $164K | Hold |
2,781
| – | – | 0.04% | 126 |
|
|
2021
Q3 | $120K | Buy |
2,781
+945
| +51% | +$41.9K | 0.03% | 133 |
|
|
2021
Q2 | $72K | Buy |
1,836
+86
| +5% | +$3.34K | 0.02% | 142 |
|
|
2021
Q1 | $63K | Buy |
1,750
+730
| +72% | +$25.9K | 0.02% | 152 |
|
|
2020
Q4 | $38K | Buy |
1,020
+124
| +14% | +$4.55K | 0.01% | 181 |
|
|
2020
Q3 | $31K | Hold |
896
| – | – | 0.01% | 251 |
|
|
2020
Q2 | $28K | Hold |
896
| – | – | 0.02% | 126 |
|
|
2020
Q1 | $28K | Sell |
896
-527
| -37% | -$18K | 0.02% | 116 |
|
|
2019
Q4 | $53K | Hold |
1,423
| – | – | 0.03% | 121 |
|
|
2019
Q3 | $49K | Sell |
1,423
-827
| -37% | -$30.1K | 0.03% | 121 |
|
|
2019
Q2 | $92K | Buy |
2,250
+827
| +58% | +$32.8K | 0.05% | 103 |
|
|
2019
Q1 | $57K | Hold |
1,423
| – | – | 0.03% | 117 |
|
|
2018
Q4 | $59K | Hold |
1,423
| – | – | 0.04% | 104 |
|
|
2018
Q3 | $59K | Buy |
+1,423
| New | +$54.8K | 0.04% | 94 |
|
Other funds holding PFE
Canton Hathaway's PFE Position: Q2 2026 in Review
Canton Hathaway held its Pfizer (PFE) position steady in Q2 2026 at 4,654 shares worth $112K. The position accounts for 0.02% of the portfolio, ranked #161.
Canton Hathaway first reported a position in PFE in Q3 2018 and has held it in 32 quarters since. The position peaked at $334K in Q3 2024. 2,818 funds tracked by Wall St. Rank hold PFE as of Q2 2026.
- Canton Hathaway held 4,654 shares of Pfizer worth $112K as of Q2 2026.
- Canton Hathaway left its Pfizer share count unchanged in Q2 2026.
- Pfizer made up 0.02% of Canton Hathaway's portfolio in Q2 2026, its #161 holding.
- Canton Hathaway first reported a position in Pfizer in Q3 2018 and has held it in 32 quarters since.
- Canton Hathaway's Pfizer position peaked at $334K in Q3 2024.
- 2,818 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.
Based on Canton Hathaway's 13F filing for Q2 2026, filed 6 Aug 2026.